Compare Stocks

AFC Ajax NV operates a football club primarily in the Netherlands. It also operates a stadium and an youth academy. The company was founded in 1900 and is based in Amsterdam, the Netherlands.

Bellway p.l.c., together with its subsidiaries, engages in the home building business in the United Kingdom. The company builds and sells homes ranging from one-bedroom apartments to six-bedroom family homes, as well as provides homes to housing associations for social housing. It offers homes under Bellway, Ashberry, and Bellway London brands. The company was founded in 1946 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Bénéteau S.A. designs, manufactures, and sells boats and leisure homes in France and internationally. It provides boats under the Beneteau, Jeanneau, Lagoon, Prestige, Four Winns, Scarab, WellCraft, EXCESS, and Delphia brand names; and leisure homes under the IRM, O'HARA, and Coco Sweet brand names. The company also offers bandofbaots.com, a community services platform for purchase and sale of new or used boats; lease purchase, credit, and insurance services through SGB Finance; and inventory and retail finance solutions. Bénéteau S.A. was founded in 1884 and is headquartered in Saint Gilles Croix de Vie, France. Bénéteau S.A. operates as a subsidiary of BERI 21 S.A.

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies in China and the U.S. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and Phase I for pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; and CT011, which is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, which targets CD19 that is in Phase I/II clinical trial for the treatment of B cell non-Hodgkin's lymphoma; CT0180, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma; and CT0181, which targets Glypican-3 that is in Phase I clinical trial for patients with Glypican-3 positive hepatocellular carcinoma. In addition, the company is developing CT0590, which targets B-cell maturation antigen that is in pre-clinical stage for the treatment of relapsed/refractory multiple myeloma; CT048, which targets Claudin 18.2 that is in pre-clinical stage for the treatment of gastric/gastroesophageal junction and pancreatic cancer; KJ-C2112, an epidermal growth factor receptor/variant III of epidermal growth factor receptor, which is in pre-clinical stage for the treatment of glioblastoma; and KJC2113 that targets mesothelin, as well as KJ-C2114 that are in pre-clinical stage for the treatment of solid tumors. Further, it is developing AB011, which is in Phase I clinical trial for the treatment of gastric/pancreatic cancer. The company was founded in 2014 and is headquartered in Shanghai, China.